Pharma BD Deal Intelligence

Element Biosystems, LLC / Standard BioTools Inc.

2026 · Asset Purchase · $6M · Pending

Standard BioTools entered a definitive agreement on September 30, 2026 to sell its Mass Cytometry business to Element Biosystems, LLC, an acquisition vehicle formed by GMT Venture Partners, LLC, for US$5.5 million in cash payable at closing subject to customary adjustments. The agreement followed an unsolicited acquisition proposal from GMT Venture on August 29, 2026; the Standard BioTools board determined the Element proposal was superior to the previously announced Multiplex Bio transaction, which the parties mutually agreed to terminate. Relative to the terminated Multiplex Bio agreement, the Element transaction removes an obligation to provide a US$10 million working capital loan, increasing the Standard BioTools net cash position by approximately US$15 million after termination and transaction fees. Closing remains subject to Standard BioTools stockholder approval and completion of its pending merger with Treeline Biosciences.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals